LivaNova PLC $LIVN Shares Sold by Aberdeen Group plc

Aberdeen Group plc trimmed its position in shares of LivaNova PLC (NASDAQ:LIVN) by 24.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 246,293 shares of the company’s stock after selling 80,493 shares during the quarter. Aberdeen Group plc owned approximately 0.45% of LivaNova worth $12,901,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Invesco Ltd. raised its stake in shares of LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after buying an additional 902,447 shares during the last quarter. Scopia Capital Management LP acquired a new stake in shares of LivaNova in the second quarter valued at approximately $36,657,000. Artisan Partners Limited Partnership increased its stake in shares of LivaNova by 112.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock worth $56,167,000 after purchasing an additional 661,480 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of LivaNova by 30.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after purchasing an additional 478,525 shares in the last quarter. Finally, M&G PLC acquired a new position in shares of LivaNova during the 2nd quarter worth approximately $11,762,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

NASDAQ LIVN opened at $67.89 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $68.25. The stock has a market cap of $3.71 billion, a PE ratio of -16.97 and a beta of 0.97. The firm’s fifty day moving average price is $63.93 and its two-hundred day moving average price is $58.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Stifel Nicolaus increased their target price on LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Robert W. Baird set a $75.00 price objective on LivaNova in a research report on Tuesday, December 16th. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. The Goldman Sachs Group reissued a “neutral” rating and issued a $66.00 target price on shares of LivaNova in a research note on Friday, January 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $85.00 price target on shares of LivaNova in a research note on Thursday. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $71.11.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.